ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
| Status: | Withdrawn |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 1/20/2019 |
| Start Date: | November 2018 |
| End Date: | December 2019 |
A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA™ (Anti-C5) in Combination With EYLEA® in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in
combination with Eylea® in treatment experienced subjects with idiopathic polypoidal
choroidal vasculopathy
combination with Eylea® in treatment experienced subjects with idiopathic polypoidal
choroidal vasculopathy
Inclusion Criteria:
- Diagnosis of IPCV
- Patients must have had 3 sequential Eylea injections within the previous 4 months
Exclusion Criteria:
- Intravitreal treatment in the study eye prior to screening, regardless of indication,
except 3 prior injections of Eylea
- History or evidence of severe cardiac disease
- Any major surgical procedure within one month of trial entry
- Subjects with a clinically significant laboratory value
- Any treatment with an investigational agent in the past 60 days for any condition
- Women who are pregnant or nursing
- Known serious allergies to the fluorescein dye, ICG dye, iodine, povidone iodine, or
to the components or formulation of either Zimura or Eylea
We found this trial at
1
site
Click here to add this to my saved trials
